Insulin β Chain Peptide (15-23) 

Insulin β Chain Peptide (15-23) is one of the earliest antigenic epitopes to which CD8 T-cells respond^[1][2][3].

CD8 T-cells purified from 5- to 8-week-old G9Cα^−/−.NOD mice produces IFN-γ and TNF-α in response to Insulin β Chain Peptide (15-23) (1 μg/mL, 24 h)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Insulin β Chain Peptide (15-23) (50 μg, i.p.) together with CpG 1826 oligonucleotides promotes very rapid diabetes development in G9Cα^−/−.NOD mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1009.18

C₄₄H₇₂N₁₂O₁₃S

247044-67-3

Solid

White to off-white

Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly

LYLVCGERG

Room temperature in continental US; may vary elsewhere.

polypeptide, sealed storage, away from moisture and light, under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (polypeptide, sealed storage, away from moisture and light, under nitrogen)

• [1]. Amrani A, et al. Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature. 2000;406(6797):739-742.  [Content Brief]

  [2]. Takaki T, et al. Requirement for both H-2Db and H-2Kd for the induction of diabetes by the promiscuous CD8+ T cell clonotype AI4. J Immunol. 2004;173(4):2530-2541.  [Content Brief]

  [3]. Wong FS, et al. Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes. 2009 May;58(5):1156-64.  [Content Brief]